The Immunotherapy of Patients with Ovarian Cancer

Journal of Immunotherapy

Volumn 25, Issue 3, 2002, Pages 189-201

  Hwu, Patrick ^a   Freedman, Ralph S ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Immunotherapy; Ovarian cancer; T cells; Tumor antigens; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOPLATIN; CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; LIVER TOXICITY; LYMPHOKINE ACTIVATED KILLER CELL; NEUTROPENIA; ONCOGENE NEU; OVARY CANCER; PERITONEUM CANCER; PERITONEUM METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036090707     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200205000-00001     Document Type: Review

References (88)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer Statistics. CA Cancer J Clin 2001; 51:15-36.
2. Rubin SC, Randall TC, Armstrong KA, et al. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1998; 93:21-4.
3. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
4. Claus EB, Scholdkraut JM, Thompson WD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77:2318-24.
5. Ozols RF, Bundy BN, Fowler J, et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecol Oncol Group Trial (GOG 158). ASCO 1999; 18:A1373.
6. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutation sin a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68:700-10.
7. Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998; 178:670-7.
8. Ford D, Easton DF, Bishop DT, et al. Risk of cancer in BRCA-1-mutation carriers: breast cancer linkage consortium. Lancet 1994; 343:692-5.
9. Roberts AB, Anzano MA, Wakefield LM, et al. Type beta transforming growth factor: a bifunctional inhibitor of cellular growth. Proc Natl Acad Sci USA 1985; 82:119-23.
10. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 15:1401-8.
11. + cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res 1998; 4:799-809.
12. Zavadova E, Savary CA, Templin S, et al. Maturation of dendritic cells from ovarian cancer patients. Cancer Chemother Pharmacol 2001; 48:289-96.
13. Freedman RS, Kudelka AP, Kavanagh JJ, et al. Clinical and biologic effects of intraperitoneal injections of recombinant interferon-γ, and recombinant interleukin-2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res 2000; 6:2268-78.
14. Melichar B, Nash MA, Lenzi R, et al. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumor-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol 2000; 119:19-27.
15. Melichar B, Touskova M, Tosner J, et al. The phenotype of ascitic fluid lymphocytes in patients with ovarian carcinoma and other primaries. Onkologie 2001; 24:156-60.
16. Loercher AE, Nash MA, Kavanagh JJ, et al. Identification of an IL-10 producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 1999; 163:6251-60.
17. Loercher AE, Platsoucas CD, Freedman RS. Induction of IL-10-producing monocytes from peripheral blood mononuclear cells of patients with epithelial ovarian cancer cultured in the presence of rhGM-CSF and rhIL-2. (submitted) 2001.
18. Yoshino I, Peoples GE, Goedegebuure PS, et al. Association of HER2/neu expression with sensitivity to tumor specific CTL in human ovarian cancer. J Immunol 1994; 152:2393-2400.
19. Ioannides CG, Platsoucas CD, Rashed S, et al. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 1991; 51:4257-65.
20. Freedman RS, Tomasovic B, Templin S, et al. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Meth 1994; 167:145-60.
21. Ioannides CG, Freedman RS, Platsoucas CD, et al. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol 1991; 146:1700-7.
22. Freedman RS, Ioannides CF, Mathioudakis G, et al. Novel immunologic strategies for the treatment of ovarian carcinoma based on cell surface recognition. Am J Obstet Gynecol 1992; 167:1470-8.
23. Kooi S, Freedman RS, Rodriquez-Villanueva J, et al. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes (TIL) from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res 1993; 12:429-37.
24. Freedman RS, Edwards CL, Kavanagh JJ, et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor infiltrating lymphocytes: a pilot trial. J Immunother 1994; 16:198-210.
25. Freedman RS, Platsoucas CD. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor-infiltrating lymphocytes. In: Sugarbaker PH, ed. Peritoneal Carcinomatosis: Principles of Management. Boston: Kluwer Academic Publishers, 1996:115-46.
26. Demetriou MC, Binkert B, Sukhu B, et al. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 1996; 271:12755-61.
27. Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995; 87:1463-9.
28. Pappas J, Lin WL, Helm CW, et al. Clonally expanded T cell receptor (TCR) transcripts in ovarian tumor infiltrating lymphocytes (TIL). Scand J Immunol 2001; 54(suppl):84.
29. Rabinowich H, Suminami Y, Reichert TE, et al. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1996; 68:276-84.
30. Nash MA, Lenzi R, Edwards CL, et al. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumor specimens, peritoneal exudate cells containing tumor, TIL-derived T-cell lines, and established tumor cell lines. Clin Exp Immunol 1998; 112:172-80.
31. Loganadane LD, Berge N, Legrand C, et al. Endothelial cell proliferation regulated by cytokines modulates thrombospondin-1 secretion into the subendothelium. Cytokine 1997; 9:740-6.
32. Brown LF, Guidi AJ, Schnitt SJ, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999; 5:1041-56.
33. Merle B, Durussel L, Delmas PD, et al. Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain. J Cell Biochem 1999; 75:538-46.
34. Yeo TK, Brown L, Dvorak HF. Alterations in proteoglycan synthesis common to healing wounds and tumors. Am J Path 1991; 138:1437-50.
35. Adany R, Heimer R, Caterson B, et al. Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. J Biol Chem 1990; 265:11389-96.
36. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-b by the proteoglycan decorin. Nature 1990; 346:281-4.
37. Lieubeau B, Heymann MF, Henry F, et al. Immunomodulatory effects of tumor-associated fibroblasts in colorectal tumor development. Int J Cancer 1999; 81:629-36.
38. Shevach EM. Regulatory T cells in autoimmunity. Annu Rev Immunol 2000; 18:423-49.
39. Woo EY, Chu CS, Goletz K, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61:4766-72.
40. Greenburg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991; 49:281-355.
41. Freedman RS. Recent immunologic advances affecting the management of ovarian cancer. In: Quillan EJ, Wharton JT, eds. Clin Obstet Gynecol, Vol. 28. Philadelphia: Harper and Row, 1985:849-67.
42. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 1997; 89:480-7.
43. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv 2001; 46:149-68.
44. Berek JS, Welander C, Schink JC, et al. A phase I-II trial of intraperitoneal cisplatin and α-interferon in patients with persistent epithelial ovarian cancer. Gynecol Oncol 1991; 40:237-43.
45. Edwards RP, Gooding W, Lembersky BC, et al. Comparison of toxicity and survival after intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 1997; 15:3399-3407.
46. Pujade-Lauraine E, Guastella JP, Colombo N, et al. Intraperitoneal recombinant interferon-gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996; 14:343-50.
47. Stewart JA, Belinson JL, Moore AL, et al. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 1990; 50:6302-10.
48. Markman M, Berek JS, Blessing JA, et al. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecol Oncol Group phase II trial of IP cisplatin and recombinant α-interferon. Gynecol Oncol 1992; 45:3-8.
49. Frasci G, Tortoriello A, Facchini G, et al. Intraperitoneal (ip) cisplatin-mitoxantrone-interferon-α2b in ovarian cancer patients with minimal residual disease. Gynecol Oncol 1993; 50:60-7.
50. Nardi M, Cognetti F, Pollera CF. Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study. J Clin Oncol 1990; 8:1036-41.
51. Freedman RS, Lenzi R, Kudelka AP, et al. Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines, Cell Mol Ther 1998; 4:121-40.
52. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998; 58:2489-99.
53. Freedman RS, Gutterman JU, Wharton JT, et al. Leukocyte interferon (IFN-α) in patients with epithelial ovarian carcinoma. J Biol Resp Mod 1983; 2:133-8.
54. Berek JS, Markman M, Stonebraker B, et al. Intraperitoneal interferon-α in residual ovarian carcinoma: a phase II gynecologic oncology group study. Gynecol Oncol 1999; 75:10-4.
55. Welander CE, Homesley HD, Reich SD, et al. A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma. Am J Clin Onc 1988; 11:465-9.
56. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Medicine 1996; 335:1950-5.
57. Rosenberg SA, Lotze M, Yang P, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210:474-84.
58. Abdulhay G, DiSaia PJ, Blessing JA, et al. Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a Gynecol Oncol Group study. Am J Obstet Gynecol 1985; 152:418-23.
59. Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature 2001; 411:380-4.
60. Wang RF. Human tumor antigens: implications for cancer vaccine development. J Mol Med 1999; 77:640-55.
61. Strausberg RL, Buetow KH, Emmert-Buck MR, et al. The cancer genome anatomy project: building an annotated gene index. Trends Genet 2000; 16:103-6.
62. Lapointe R, Royal RE, Reeves ME, et al. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC Class I and II epitopes from the melanoma antigen glycoprotein 100. J Immunol 2001; 167:4758-64.
63. Parkhurst MR. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2. Cancer Res 1998; 58:4895-4901.
64. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91:3515-9.
65. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94:1914-8.
66. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187:265-70.
67. Zeng G, Wang X, Robbins PF, et al. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA 2001; 98:3964-9.
68. Zeng G, Touloukian CE, Wang X, et al. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 2000; 165:1153-9.
69. Bownds S, Tong-On P, Rosenberg SA, et al. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution. J Immunother 2001; 24:1-9.
70. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001; 107:477-84.
71. Brossart P, Stuhler G, Flad T, et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer 1998; 58:732-6.
72. Fisk B, Blevins TL, Wharton JT, et al. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181:2100-17.
73. Disis ML, Smith JW, Murphy AE, et al. in vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu proto-oncogene protein. Cancer Res 1994; 53:1071-6.
74. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu + tumors. Cancer Res 1998; 58:4902-8.
75. Vonderheide RH, Hahn WC, Schultze JL, et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10:673-9.
76. Minev B, Hipp J, Firat H, et al. Cytotoxic T cell immunity against telomerase reverse transcription in humans. Proc Natl Acad Sci USA 2000; 97:4796-4801.
77. Ayyoub M, Migliaccio M, Guillaume P, et al. Lack of tumor recognition by hTERT peptide 540-548 specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 2001; 31:2642-51.
78. Galmozzi E, Tomassetti A, Sforzini S, et al. Exon 3 of the alpha folate receptor gene contains a 5´ splice site which confers enhanced ovarian carcinoma specific expression. FEBS Lett 2001; 502:31-4.
79. Coney LR, Tomassetti A, Carayannopoulos L, et al. Cloning of a tumor-associated antigen: MOv 18 and MOv 19 antibodies recognize a folate-binding protein. Cancer Res 1991; 51:6125-32.
80. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996; 93:136-40.
81. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-7.
82. Rosenberg SA, Yanenelli JR, Yang JC. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 1994; 86:1159-66.
83. Dadmarz RD, Ordoubadi A, Mixon A, et al. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Cancer J Sci Am 1996; 2:263-72.
84. Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 1993; 178:361-6.
85. Hwu P, Yang JC, Cowherd R, et al. in vivo antitumor activity of T-cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995; 55:3369-73.
86. Parker LL, Do MT, Westwood JA, et al. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 2000; 11:2377-87.
87. Treisman J, Hwu P, Yannelli JR, et al. Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid. Cell Immunol 1994; 156:448-57.
88. Liu K, Rosenberg SA. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol 2001; 167:6356-65.